Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CrystalGenomics To Push Fabl Inhibitor Trials With Govt Support

This article was originally published in PharmAsia News

Executive Summary

Following the positive outcome of a US Phase IIa study for its pioneering Fabl inhibitor, CrystalGenomics plans to proceed with global clinical trials of the first-in-class antibiotic for MRSA in improved dosage forms, with some financial help from South Korea’s government.

You may also be interested in...

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Genexine Counting On Hyleukin-7’s Potential As Versatile I-O Booster

Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.

VGXI Gears To Support Production Of New Coronavirus Vaccine

VGXI, a contract manufacturer of plasmid DNA and US subsidiary of Korea’s GeneOne Life Science, joins in the R&D efforts for a DNA vaccine against the new Wuhan coronavirus, using its proprietary manufacturing platform as part of a new agreement with Inovio.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts